false
OasisLMS
Catalog
2021 Annual Meeting Biologics Access Pass
The Business of OrthoBiologics in Clinical Practic ...
The Business of OrthoBiologics in Clinical Practice
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The speaker highlights orthobiologics as a rapidly growing $4.5-$10 billion global market addressing increasing osteoarthritis cases. These treatments appeal to patients seeking alternatives to total joint replacement and present a valuable business opportunity. Reimbursement is complex, with varied insurance coverage and most services considered experimental, often requiring advanced beneficiary notifications (ABNs) for billing. Coding guidance includes use of codes for VSCO, PRP (0232T), BMAC, and adipose tissue (20999), though many treatments remain cash-pay, non-covered services. Successful practices treat orthobiologics as ancillary services, emphasizing transparency, regulatory compliance, outcome tracking, and ethical patient communication.
Asset Caption
Dr. Louis McIntyre
Keywords
orthobiologics
osteoarthritis treatment
joint replacement alternatives
medical billing codes
patient communication
×
Please select your language
1
English